
A recent study demonstrated that glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists significantly decreased the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The findings showed that circulating GLP-1 and GIP concentrations during an oral glucose tolerance test provided hepatoprotective effects on MASLD risk. While GLP-1 receptor expression had a minimal impact, GIP receptor expression significantly influenced MASLD risk. Moreover, mediation analysis confirmed that GIP receptor expression offered protection against MASLD, highlighting both direct and mediated effects through weight loss and improved glycemic control. These results indicate the potential of GLP-1/GIP receptor agonists in treating liver diseases associated with metabolic dysfunction.
Like
Save
Share